A Phase II Single-Arm Study to Investigate Tepotinib Combined with Cetuximab in RAS/BRAF Wild-Type Left- Sided Metastatic Colorectal Cancer (mCRC) Patients Having Acquired Resistance to Anti-EGFR Antibody Targeting Therapy Due to MET Amplification

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE) (CanStem303C) »